All Posts

by John F. Heerdink, Jr. April 14, 2025

The Significant Impact Of Osteoarthritis and Eupraxia Pharmaceuticals’ Potentially Groundbreaking Work – $EPRX $IBB $XBI

Osteoarthritis (OA) is a degenerative joint disease and the most common form of arthritis, affecting millions worldwide. Characterized by the breakdown of cartilage—the protective tissue at the ends of bones—OA leads to pain, stiffness, swelling, and loss of mobility in affected joints. Commonly impacted areas include the knees, hips, hands, spine, and neck. While OA often develops gradually with age, it can also result from joint injuries or genetic defects in cartilage. The condition is not just a physical ailment; it can severely affect quality of life, contributing to depression, sleep disturbances, and fatigue.

The Challenges of Treating Osteoarthritis

Current treatments for OA focus on managing symptoms rather than reversing joint damage. Pain relief strategies include physical therapy, weight management, oral medications like NSAIDs, and intra-articular injections such as corticosteroids. However, these options often come with limitations: poor safety profiles, inadequate efficacy, or short durations of relief. For example, corticosteroids are effective but provide only temporary relief and may cause unwanted side effects.

Given the prevalence of knee OA—affecting over 30 million people in the U.S. alone—and its significant impact on daily life, there is a pressing need for innovative therapies that offer longer-lasting relief without compromising safety.

Eupraxia Pharmaceuticals: A New Approach to OA Treatment

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company based in Victoria, Canada, is at the forefront of addressing this unmet medical need. The company’s lead product candidate for OA is EP-104IAR, an extended-release intra-articular injection designed specifically for knee OA. This groundbreaking therapy leverages Eupraxia’s proprietary DiffuSphere™ technology to deliver highly localized and sustained doses of fluticasone propionate—a potent corticosteroid—directly into the affected joint.

How EP-104IAR Works

The novel formulation encapsulates fluticasone propionate within a microns-thin polymer membrane that allows the drug to diffuse slowly into the knee joint over six months. This extended release aims to provide durable pain relief while minimizing systemic side effects often associated with corticosteroids. The design also enables simultaneous treatment of both knees for patients experiencing bilateral pain—a significant advantage given that 70% of knee OA patients suffer in both joints.

EP-104IAR has additional practical benefits: it requires no refrigeration, boasts a long shelf life, and integrates seamlessly into existing delivery techniques used by physicians.

Clinical Success: Phase 2 Trials

Eupraxia’s Phase 2b SPRINGBOARD trial demonstrated promising results for EP-104IAR. The study involved 318 patients with moderate-to-severe knee OA pain across multiple sites in Europe. EP-104IAR met its primary endpoint with statistically significant improvements in WOMAC Pain scores at 12 weeks compared to placebo (p=0.004). Secondary endpoints also showed substantial benefits in function and overall response rates.

Notably, MRI data from an exploratory sub-study indicated that EP-104IAR does not negatively impact cartilage health or exacerbate inflammation—critical findings that support its continued development as a safe and effective therapy.Furthermore, the drug exhibited stable plasma concentrations of fluticasone propionate with minimal changes in glucose and cortisol levels, underscoring its favorable safety profile.

Lancet Rheumatology, a leading independent, peer-reviewed journal committed to sharing progressive content relevant to rheumatology specialists worldwide, published Eupraxia’s Phase 2 data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis. Publication of Eupraxia’s Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet Rheumatology, Eupraxia’s EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportionate concentrations in plasma. You may read the Lancet Publication regarding Eupraxia at this link.

Fast Track Designation and Future Development

The U.S. FDA granted Fast Track designation to EP-104IAR in recognition of its potential to address the significant unmet medical need for knee OA treatment. This designation facilitates expedited review processes and frequent interactions with regulatory authorities—a vital step as Eupraxia prepares for Phase 3 trials.

Beyond knee OA, Eupraxia is exploring additional applications for its DiffuSphere™ technology in other inflammatory joint conditions and diseases such as eosinophilic esophagitis (EoE). These efforts reflect the company’s broader mission to transform drug delivery systems across multiple therapeutic areas.

Transforming Osteoarthritis Care

Eupraxia Pharmaceuticals’ innovative approach represents a potential paradigm shift in OA treatment. By addressing key challenges—such as short-duration relief and systemic side effects—EP-104IAR offers hope for millions suffering from this debilitating condition. With its robust clinical data and advanced formulation technology, Eupraxia is poised to redefine how we manage knee OA pain while improving patients’ quality of life.

What Wall Street Is Saying…

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has garnered significant attention from stock analysts, reflecting optimism about its innovative approach to treating osteoarthritis and other inflammatory conditions. The company currently holds a consensus rating of “Strong Buy” from four Wall Street analysts, with price targets ranging from $9 to $12 over the next twelve months. The average price target of $10.50 represents a potential upside of over ~200% compared to the current trading price of ~$3.12. Analysts have highlighted Eupraxia’s promising clinical trial results for EP-104IAR and its proprietary DiffuSphere™ technology as key drivers of this bullish outlook. This positive sentiment underscores the market’s confidence in Eupraxia’s ability to address unmet medical needs while delivering shareholder value through its innovative pipeline.

Citations:

by John F. Heerdink, Jr. April 10, 2025

Health & Human Services Secretary RFK Jr. Confirms Shift To Working On ‘Multiple Antigen Vaccines’ During CBS Interview – $NVAX $GOVX $XBI

In his first network TV interview since becoming Health and Human Services secretary, Robert F. Kennedy Jr. spoke with CBS News chief medical correspondent Dr. Jon LaPook about a range of topics, including measles, food additives, weight loss drugs & their shift away from single antigen COVID-19 vaccines i.e. Novavax (NVAX)’s vaccine for COVID-19 towards the development of multiple antigen COVID-19 vaccines. A multiple antigen vaccine is a single vaccine that contains two or more antigens targeting a particular infectious disease such as COVID-19. Such vaccines are designed to provide immune protection by inducing both the antibody and cellular (e.g., T-cells) immunity providing a more robust and durable immune protection, utilizing both “arms of the immune system”. This differs from a combination vaccine which may incorporate two or more vaccines against different infectious targets in a single injection, such as targeting DTaP (diphtheria, tetanus, pertussis), MMR (measles, mumps, rubella), and DTap-Hib. You can learn more by watching the interview here:

One such company that could benefit from RFK, Jr.’s / HHS ‘s shifting priorities towards multiple antigen vaccines is GeoVax labs, Inc. (NASDAQ: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases. GeoVax’s infectious disease vaccines are based upon a vaccine platform that allows for multiple antigens to be included into the single vaccine construct, unlike other vaccine platforms such as mRNA, protein adjuvant and other vaccine platform technologies, most of which are restricted to allowing a single antigen inclusion in a vaccine. This is possible through the use of the company’s MVA vaccine platform, a large virus capable of incorporating multiple antigens into a vaccine platform. Utilizing MVA, as a vaccine vector, allows for the targeting of multiple sites on a pathogen or even a cancer cell. Doing this is intended to result in a more robust and durable protective immune response. In addition, using MVA as a vaccine platform allows for the construction of vaccines which are capable of generating virus-like particles (VLPs) in the person receiving the vaccine. The production of VLPs in the person being vaccinated is intended to mimic viral production that occurs in a natural infection, stimulating both the humoral (antibody) and cellular (T-cell) arms of the immune system to recognize, prevent, and control future infections.

MVA vectored vaccines can elicit durable (long-acting) immune responses while also possessing an excellent safety profile. MVA-VLP vaccines are designed to mimic authentic viruses in form but are not infectious or capable of replicating. As a result, VLPs can cause the body’s immune system to recognize and kill targeted infectious agents to prevent an infection or can be designed to target cancerous cells resulting in inhibited growth or destruction of tumors. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease.

One of the biggest challenges with developing traditional VLP-based vaccines is the manufacture and collection of the VLPs utilizing traditional manufacturing equipment. In contrast, by utilizing the GeoVax approach, designing the vaccine to produce VLPs in the body of the vaccinated individual, many of the manufacturing challenges, issues, and costs are avoided.

GeoVax designs their MVA-VLP vaccines such that, when VLPs for viruses like Ebola or Marburg are produced in vivo (in the cells of the recipient), they present the viral protein antigens to the host cells in a manner similar to those of a natural infection.

Note that MVA, as a vaccine, was developed in the 1960s/1970s as a safer smallpox vaccine for use in immune-compromised individuals, pregnant women and children. The safety and utility of MVA as a vaccine and as a vaccine platform are well documented and recognized by public health authorities worldwide. GeoVax obtained rights from the U.S. NIH to develop MVA as a vaccine for smallpox and Mpox (GEO-MVA), as well as also utilizing MVA as a vaccine vector against infectious diseases and even cancer (tumor associated antigens). GeoVax also holds exclusive worldwide rights to use the City of Hope Medical Center’s synthetic MVA (sMVA) platform for the manufacture and distribution of COVID-19 vaccines including GEO-CM04S1, their multi-antigenic COVID-19 vaccine currently in multiple Phase 2 studies, including having received a Project NextGen award of approximately $400 million during 2024 in support of a 10,000 patient Phase 2b evaluation of GEO-CM04S1 versus an mRNA authorized COVID-19 vaccine.

In summary, the GeoVax MVA vaccine platform is believed to provide several benefits and advantages:

Safety: Safety for MVA has been demonstrated as a smallpox vaccine in more than 120,000 subjects, including immunocompromised individuals. In human clinical trials, our HIV vaccine candidate has demonstrated outstanding safety.
Durability: Our technology can promote highly durable (long-lasting) vaccine responses, lasting up to one year.
Limited pre-existing immunity to vector: Pre-existing immunity is a condition where a vaccinated patient’s response is muted due to prior exposure to a virus. The risk of pre-existing immunity to MVA is considered low as MVA vaccines against smallpox ended in most countries in the mid-1970s following the successful worldwide eradication of smallpox.
Ability to generate VLPs in the patient: Non-infectious VLPs can more closely mimic natural infections resulting in activation of both the humoral and cellular arms of the immune system.
Protection against Mpox and smallpox: MVA vectored vaccines have been shown to maintain the inherent activity of MVA against Mpox and smallpox.
Long-term product stability: MVA formats provide more than 6 years of storage.
Distribution advantages: MVA does not require ultra-cold storage conditions and can be lyophilized (freeze-dried) which can simplify vaccine product distribution and administration.

More on Advanced High-Capacity Manufacturing of MVA-based Vaccines

GeoVax is transitioning to an advanced MVA manufacturing process intending to significantly increase the manufacturing yield and volume capacity in response to potential epidemic and pandemic needs. The advanced MVA manufacturing utilizes a patented, proprietary continuous avian cell line system (AGE.1) for manufacturing MVA-based vaccines and immunotherapies. Currently, MVA vaccines are manufactured in cells cultured from chicken embryonic fibroblasts (CEF), a suboptimal and time-consuming process useful primarily for niche markets and stockpile reserves. Transitioning to the AGE.1-based system is anticipated to provide lower-cost, scalable versatility for broad MVA vaccine and immunotherapy applications. In addition, the advanced MVA manufacturing process is intended to expand MVA-based vaccine production from stockpile-based solutions for niche medical markets to include the ability to respond to world needs on a timely basis, whenever and wherever they arise. GeoVax believes it will be the first supplier of MVA-based vaccines to implement such a transformative manufacturing process and intends to become the first U.S.-based supplier of the MVA vaccine to prevent Mpox, smallpox and other pox-related viruses. The initial candidates for the advanced manufacturing process include GEO-MVA (addressing Mpox and smallpox) and GEO-CM04S1 (COVID-19 vaccine).

Continues to Strengthen its Pandemic Preparedness and Biodefense Vaccine Portfolio

On April 9, 2025, GeoVax announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Patent Application No. 18/394,555 titled “Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix Protein (VP40).” The allowed claims generally cover prevention of Marburg virus infection utilizing GeoVax’s proprietary MVA-based Marburg vaccine. Previous presentations of data from nonhuman primate studies demonstrated that immunization with GeoVax’s vaccine candidate, GEO-MM01, conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus. Vaccination protected from viremia, weight loss and death following challenge with a lethal Marburg virus dose. Evaluation of immune responses following vaccination demonstrated the presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. GeoVax is currently evaluating study designs to assess the potential for administering different dose levels of the vaccine and different routes of vaccine delivery to optimize utility and efficacy. Marburg virus (MARV) is a hemorrhagic fever virus of the Filoviridae family, which also includes Ebola virus (Ebvola Zaire and Ebola Sudan), and causes severe human disease with up to a 90% fatality rate. The Marburg virus is transmitted to people from fruit bats, and human-to-human transmission occurs through direct contact with bodily fluids, or contaminated surfaces and materials. MARV is rated by the World Health Organization (WHO) as a Risk Group 4 Pathogen. In the United States, the NIH/National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent. MARV typically appears in sporadic outbreaks throughout Africa and the virus continues to pose potential public health and biodefense threats. There are currently no licensed vaccines or therapeutics against the diseases caused by MARV.

David Dodd, GeoVax Labs., Inc. (NASDAQ: GOVX) President and CEO

David Dodd, GeoVax President and CEO, commented, “While our focus and development priorities continue to be our next-generation COVID-19 vaccine, our Mpox/smallpox vaccine and cancer immunotherapy programs, developing vaccines against lethal hemorrhagic fever viruses represents our commitment to addressing highly fatal endemic threats throughout the world. Such viruses have mortality rates between 50%-90% depending on the specific virus strain. Our team is committed to supporting the successful advancement of such a vaccine, as we recognize the critically important medical and biodefense need, reflected by the inclusion of Marburg virus in the FDA Priority Review Voucher program. Within the critically needed area of hemorrhagic fever viruses, GeoVax has successfully developed vaccine candidates addressing Ebola Zaire, Ebola Sudan and Marburg, all having demonstrated impressive results when evaluated in non-human primates. The USPTO’s recognition of our Marburg vaccine technology further validates our approach and underscores the growing value of our wholly owned, co-owned, and in-licensed intellectual property estate, now standing at over 135 granted or pending patent applications spread over 23 patent families. Our focus extends beyond individual product candidates—we are building a broad, durable defense platform against hemorrhagic fever viruses. We believe this strategy, supported by compelling preclinical data and prioritized by global health authorities, positions GeoVax to play a central role in pandemic preparedness and biodefense.”

More About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin^® combined with an immune checkpoint inhibitor is planned. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

by John F. Heerdink, Jr. April 9, 2025

GeoVax Successfully Adds To Burgeoning Intellectual Property Portfolio – $GOVX $MRK $XBI

GeoVax Labs, Inc. (NASDAQ: GOVX), a trailblazer in the biotechnology arena, is steadily carving its niche in the development of vaccines and immunotherapies targeting infectious diseases and cancers. The company recently celebrated a significant milestone: the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Patent Application No. 18/394,555 titled “Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix Protein (VP40).” The allowed claims generally cover prevention of Marburg virus infection utilizing GeoVax’s proprietary MVA-based Marburg vaccine. This patent underscores GeoVax’s technical prowess in leveraging modified viral vectors to stimulate robust immune responses.

A Growing Arsenal of Intellectual Property

This achievement adds to GeoVax’s burgeoning intellectual property portfolio, which now boasts over 120 granted or pending patents across 24 families. The company’s proprietary Modified Vaccinia Ankara (MVA) platform has proven versatile, supporting not only infectious disease vaccines like those for Zika and Mpox, but also groundbreaking cancer therapies. For instance, their MVA-VLP-MUC1 immunotherapy candidate has shown promise in preclinical studies, achieving significant reductions in tumor growth when paired with immune checkpoint inhibitors.

Advancing Clinical Programs

GeoVax is also making waves with its next-generation COVID-19 vaccine, GEO-CM04S1. This dual-antigen vaccine is undergoing Phase 2 clinical trials as both a primary vaccine for immunocompromised patients and a booster for healthy adults who previously received mRNA vaccines. Early data suggest that GEO-CM04S1 may offer superior immune responses compared to existing options, particularly in vulnerable populations such as those with chronic lymphocytic leukemia (CLL).

Meanwhile, the company is gearing up for a pivotal 10,000-participant Phase 2b trial under BARDA’s Project NextGen initiative. This study aims to compare GEO-CM04S1 against FDA-approved mRNA vaccines, potentially positioning it as a game-changer in the COVID-19 vaccine landscape.

Expanding Horizons in Oncology

In the oncology domain, GeoVax’s Gedeptin® program is entering an exciting phase. Following promising results from earlier trials, the company plans to initiate a Phase 2 study evaluating this gene-directed therapy for recurrent head and neck cancers. By combining Gedeptin® with immune checkpoint inhibitors i.e. Merck’s (MRK) blockbuster Keytruda, GeoVax aims to address unmet needs in solid tumor treatment.

A Vision for Global Health

Beyond its pipeline, GeoVax is committed to addressing global health challenges. Its GEO-MVA vaccine candidate for Mpox and smallpox exemplifies this mission. Designed for scalability and minimal refrigeration requirements, this vaccine could play a pivotal role in biosecurity and underserved regions worldwide.

Looking Ahead

As GeoVax strides into 2025, it does so with an air of optimism and purpose. With a robust pipeline addressing markets valued at over $55 billion globally, the company is poised to deliver meaningful advancements in both public health and oncology. Whether through strategic partnerships or cutting-edge innovation, GeoVax continues to redefine what’s possible in biotechnology.

Citations:
[1] https://www.galifesciences.org/geovax-receives-notice-of-allowance-for-zika-vaccine-patent/utm_sourcerssutm_mediumrssutm_campaigngeovax-receives-notice-of-allowance-for-zika-vaccine-patent
[2] https://geovax.com/investors/press-releases/geovax-reports-2024-year-end-financial-results-and-provides-business-update
[3] https://www.geovax.com/investors/press-releases/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-2
[4] https://www.geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs
[5] https://www.stocktitan.net/news/GOVX/geo-vax-receives-notice-of-allowance-for-cancer-vaccine-8zh0kvjpsrwj.html
[6] https://www.channelchek.com/news-channel/geovax-labs-govx-geovax-receives-allowance-for-new-patent-covering-vaccine-platform-technologies
[7] https://www.globenewswire.com/search/organization/GeoVax%CE%B4%2520Inc%C2%A7
[8] https://finance.yahoo.com/quote/GOVX/press-releases/
[9] https://geovax.com/investors/press-releases/geovax-achieves-significant-progress-in-next-generation-covid-19-vaccine-development-throughout-2024
[10] https://finance.yahoo.com/quote/GOVX/
[11] https://finance.yahoo.com/news/geovax-receives-uspto-notice-allowance-130000606.html
[12] https://www.geovax.com
[13] https://geovax.com/investors/press-releases/geovax-to-review-2024-progress-at-biotech-showcase-during-j-p-morgan-healthcare-week-2025
[14] https://twitter.com/Geovax_News/status/1909998524277678214
[15] https://finance.yahoo.com/news/geovax-achieves-significant-progress-next-140000313.html
[16] https://www.globenewswire.com/news-release/2024/12/09/2993794/0/en/GeoVax-Receives-Notice-of-Allowance-For-Cancer-Vaccine-Patent.html
[17] https://geovax.com/investors/press-releases
[18] https://www.geovax.com/investors/press-releases/category/geovax-recent-news
[19] https://www.stocktitan.net/news/GOVXW/
[20] https://www.globenewswire.com/news-release/2024/11/12/2979622/0/en/GeoVax-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

by John F. Heerdink, Jr. April 8, 2025

Lawrence Summers Warns of Economic Storm Clouds Ahead – $SPY $QQQ $DIA $VIX

Former Treasury Secretary Lawrence Summers has delivered a sobering outlook for the U.S. economy, suggesting that the nation may be teetering on the edge of a recession. With a near 50-50 chance of economic contraction this year, Summers points to a confluence of policy decisions under President Donald Trump’s administration as the primary culprits behind this precarious situation.

A Recipe for Uncertainty

Summers, who served in both the Clinton and Obama administrations, has been vocal about what he describes as “self-inflicted wounds” to the economy. He attributes much of the current turmoil to aggressive tariff policies, sweeping immigration restrictions, and layoffs within the federal workforce. These measures have collectively eroded consumer and business confidence, creating what Summers calls “a real uncertainty problem” that will be hard to resolve.

The Trump administration’s trade war has introduced tariffs on imports from China, the European Union, and other nations, with additional duties looming on steel and aluminum. While officials argue these policies aim to rebuild America’s manufacturing base, Summers is skeptical. He likened the administration’s rhetoric about a “transition period” for economic growth to earlier dismissals of inflation spikes as “transitory,” warning that such optimism might not hold up under scrutiny.

Economic Indicators Flashing Red

Summers has pointed out several warning signs that Americans should monitor closely. Key indicators include the slope of the yield curve, consumer intentions to make large purchases like homes or cars, and stock performance in cyclical industries. These metrics collectively paint a picture of an economy losing steam.

Indeed, recent forecasts from economists and rating agencies echo Summers’ concerns. GDP growth for 2025 is expected to slow significantly—down to 1.7% according to Goldman Sachs and Vanguard—compared to 2.8% in 2024. Inflation remains stubbornly high due to tariff-induced price pressures, while unemployment is projected to rise as job creation slows.

The Human Cost

Summers warns that the potential recession could lead to severe consequences for American families. He estimates that two million jobs could be lost nationwide, with household incomes falling by over $5k on average due to higher costs and diminished economic activity. Comparing Trump’s tariffs to the infamous Smoot-Hawley tariffs of the 1930s—which exacerbated the Great Depression—Summers advocates for a reversal of these policies before further damage is done.

Market Volatility Adds Fuel to Fire

Markets have already felt the sting of uncertainty. Last week saw a dramatic $5.4 trillion rout in global stock markets following Trump’s tariff announcements—a plunge comparable only to historic events like the 1987 crash and the 2008 financial crisis. Summers cautions that such volatility signals deeper systemic issues, urging investors to tread carefully.

A Path Forward?

While Summers remains critical of current policies, he acknowledges that reversing course could alleviate some pressure on the economy. However, he warns that without significant changes in trade policy and rhetoric from the administration, pessimism will likely deepen.

In summary, Summers paints a picture of an economy caught in a storm of its own making—a mix of policy missteps and global uncertainty that threatens growth and stability. Whether policymakers will heed his warnings remains to be seen. For now, Americans may need to brace themselves for choppy economic waters ahead.

Citations:
[1] https://www.bloomberg.com/news/articles/2025-03-11/summers-sees-near-50-50-chance-of-recession-hitting-this-year
[2] https://www.youtube.com/watch?v=yHNLsaGSaGo
[3] https://www.spglobal.com/ratings/en/research/articles/250325-economic-outlook-u-s-q2-2025-losing-steam-amid-shifting-policies-13450076
[4] https://finance.yahoo.com/news/summers-warns-more-turbulence-5-160952238.html
[5] https://lsa.umich.edu/content/dam/econ-assets/Econdocs/RSQE%20PDFs/RSQE_US_Forecast_Feb25.pdf
[6] https://nypost.com/2025/04/08/business/larry-summers-predicts-recession-2m-unemployed-due-to-tariffs/
[7] https://corporate.vanguard.com/content/corporatesite/us/en/corp/vemo/vemo-united-states.html
[8] https://www.bloomberg.com/news/videos/2025-03-22/summers-self-inflicted-wound-to-the-us-economy-video
[9] https://www.goldmansachs.com/insights/articles/why-the-us-economy-may-grow-more-slowly-than-expected
[10] https://abcnews.go.com/ThisWeek/video/tariffs-biggest-inflicted-wound-us-economy-summers-120534832
[11] https://www.jpmorgan.com/insights/outlook/economic-outlook/fed-meeting-march-2025
[12] https://www.cnn.com/2025/04/03/business/video/larry-summers-trump-global-tariffs-arena-digvid
[13] https://www.china-briefing.com/news/china-vs-us-economy-2025-outlook/
[14] https://fortune.com/2025/04/04/larry-summers-trump-masochistic-tariffs-hit-american-families/
[15] https://www2.deloitte.com/us/en/insights/economy/us-economic-forecast/united-states-outlook-analysis.html
[16] https://fortune.com/2025/03/12/larry-summers-recession-trump-tariffs-economic-outlook-wound-stock-market/
[17] https://www.ey.com/en_us/insights/strategy/macroeconomics/us-economic-outlook
[18] https://www.conference-board.org/research/us-forecast
[19] https://www.cbo.gov/publication/61187
[20] https://www.fitchratings.com/research/sovereigns/global-economic-outlook-march-2025-18-03-2025

by John F. Heerdink, Jr. April 7, 2025

South Florida-based AI-powered fintech platform Co. Janover’s Financial Triumphs and Strategic Evolution – $JNVR $NVDA

Janover Inc. (NASDAQ: JNVR), a South Florida-based AI-powered fintech platform, has reported exceptional financial results for the fourth quarter and full year of 2024, showcasing its transformative journey in the commercial real estate sector. With a bold pivot toward a subscription-first business model, Janover achieved a remarkable 488% year-over-year increase in SaaS subscription revenue, contributing to an overall 80% revenue growth for the quarter. Janover is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals as we connect the increasingly complex ecosystem that stakeholders have to manage. They currently serve more than one million web users annually, including multifamily and commercial property owners and developers applying for billions of dollars of debt financing per year, professional service providers, and thousands of multifamily and commercial property lenders including more than 10% of the banks in America, credit unions, real estate investment trusts (“REITs”), debt funds, Fannie Mae® and Freddie Mac® multifamily lenders, FHA multifamily lenders, commercial mortgage-backed securities (“CMBS”) lenders, Small Business Administration (“SBA”) lenders, and more. Their data and software offerings are generally offered on a subscription basis as software as a service (“SaaS”).

Key Financial Highlights

– Annual Recurring Revenue (ARR) surged by 194% to $812,000, signaling strong customer retention and product-market fit.
– The company improved its **quarterly net loss** by 59%, alongside a 73% boost in cash flow from operations.
– Subscription revenue skyrocketed from $32,000 in 2023 to $480,000 in 2024, now representing 23% of total revenue—a testament to the scalability of Janover’s SaaS model.

Blake Janover, CEO of Janover Inc., expressed optimism about the company’s trajectory: “Our fourth quarter results demonstrate the powerful transformation we’ve undergone, with SaaS subscription revenue up 488% year-over-year. This further validates our strategic pivot to a subscription-first business model”.

Janover’s AI Edge

Janover’s platform leverages artificial intelligence to connect borrowers and lenders in the multifamily and commercial real estate ecosystem. By addressing inefficiencies caused by data fragmentation, Janover has positioned itself as more than just another fintech marketplace—it’s a solution provider for complex industry challenges. Its suite of products, including Janover Pro and Janover AI, serves over one million web users annually, ranging from property professionals to small business owners.

NVIDIA’s AI Revolution: A Parallel Tale of Innovation

As Janover reshapes commercial real estate financing through AI, NVIDIA is revolutionizing industries with cutting-edge AI technologies. At CES 2025, NVIDIA unveiled groundbreaking innovations such as the GeForce RTX 50 Series GPUs and Project DIGITS supercomputers. These advancements highlight the company’s dominance in edge computing and on-device AI processing—a trend that aligns with enterprise demands for reduced latency and enhanced data privacy.

NVIDIA’s Latest Developments

– GeForce RTX 50 Series GPUs: Built on Blackwell architecture, these GPUs deliver unprecedented performance with 92 billion transistors and 3,352 trillion AI operations per second, redefining gaming and creative workflows through AI-driven enhancements like DLSS 4 technology.
– Project DIGITS: A personal AI supercomputer designed for developers to run sophisticated models locally, reflecting NVIDIA’s leadership in edge computing.
– Cosmos Platform: A world foundation model platform aimed at accelerating physical AI development for autonomous vehicles and robotics.

Jensen Huang, CEO of NVIDIA, emphasized the transformative potential of physical AI: “We’re entering an era where AI can proceed, reason, plan, and act—ushering in breakthroughs across robotics and autonomous systems”.

Drawing Parallels: The Intersection of AI Innovation

Both Janover and NVIDIA exemplify how artificial intelligence is reshaping industries. While Janover focuses on streamlining commercial real estate transactions through its B2B marketplace, NVIDIA is enabling advanced computational capabilities across gaming, robotics, and autonomous vehicles. Their shared commitment to leveraging AI underscores a broader trend: the integration of intelligent systems into everyday workflows.

Looking Ahead

For Janover, the future lies in scaling its SaaS offerings while maintaining its human touch—a unique value proposition in a tech-driven world. For NVIDIA, the challenge is sustaining its dominance amid growing competition from Intel and AMD while pushing boundaries in edge computing.

Together, these companies illustrate how innovation can drive growth—even in vastly different sectors. Whether it’s transforming real estate financing or powering next-gen robotics, their stories remind us that AI is not just a tool but a catalyst for change.

Citations:
[1] https://www.linkedin.com/company/janover
[2] https://finance.yahoo.com/news/nvidia-stock-sinks-as-ceo-jensen-huang-keynotes-gtc-2025-event-unveils-new-chip-lineup-134709250.html
[3] https://www.stocktitan.net/news/JNVR/janover-inc-reports-fourth-quarter-and-full-year-2024-financial-f09lx617k5es.html
[4] https://www.ces.tech/articles/2025/january/ces-2025-jensen-huang-presents-nvidias-latest-innovations/
[5] https://www.marketscreener.com/quote/stock/JANOVER-INC-157358409/news/Crypto-Industry-Leaders-Acquire-Majority-Ownership-Of-Janover-Inc-49547878/
[6] https://nvidianews.nvidia.com/online-press-kit/ces-2025-news
[7] https://www.globenewswire.com/news-release/2025/03/13/3042238/0/en/Janover-Inc-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-with-a-488-Increase-in-SaaS-Revenue-and-80-YoY-Quarterly-Growth.html
[8] https://aimagazine.com/articles/nvidias-new-ai-innovations-at-ces-2025-explained
[9] https://ir.janover.co
[10] https://www.reuters.com/technology/artificial-intelligence/nvidia-expected-reveal-details-latest-ai-chip-conference-2025-03-18/
[11] https://www.globenewswire.com/news-release/2025/04/07/3056682/0/en/New-Janover-Management-Team-Raises-Approximately-42-Million-to-Enhance-U-S-Public-Market-Digital-Asset-Treasury-Strategy.html
[12] https://techfundingnews.com/nvidia-announcements-at-ces-2025-next-gen-gpus-and-ai-breakthroughs/
[13] https://www.bloomberg.com/profile/company/JNVR:US
[14] http://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-fourth-quarter-and-fiscal-2025
[15] https://www.tipranks.com/news/company-announcements/janover-inc-closes-offering-and-adds-solana
[16] https://technologymagazine.com/articles/nvidias-new-ai-innovations-at-ces-2025-explained
[17] https://ir.janover.co/company-information
[18] https://www.nvidia.com/gtc/
[19] https://www.webull.com/news/12543300191904768
[20] https://blogs.nvidia.com/blog/nvidia-keynote-at-gtc-2025-ai-news-live-updates/

by John F. Heerdink, Jr. April 4, 2025

CXApp’s Agentic AI Transformation – $CXAI $AMZN $GOOG

CXApp Inc.(NASDAQ: CXAI, $1.42, +76% on Friday), headquartered in Palo Alto, California, is a pioneering force in workplace experience technology. The company provides an innovative enterprise platform that leverages artificial intelligence (AI) and customer experience (CX) principles to reimagine employee interactions and optimize workplace environments.

Key aspects of CXApp include:

A software-as-a-service (SaaS) platform offering native mapping, analytics, and on-device positioning technologies
Solutions for workplace experience, employee engagement, desk booking, and meeting room reservations
AI-powered tools for workplace analytics, occupancy management, and corporate communications
A mobile app that integrates over 100 enterprise tools and services, providing employees with a centralized platform for managing work activities
A focus on addressing challenges such as employee engagement, space utilization, and overall workplace satisfaction

Founded in 2023, CXApp (NASDAQ: CXAI) has quickly established itself as a trusted partner for Fortune 500 companies, with deployments in over 50 countries and 200 cities worldwide56.

CXApp Inc. has reported strong financial results for 2024, marking a successful transformation to an AI-centric subscription business model with significant improvements in key metrics and the deployment of its CXAI Platform featuring innovative products for workplace experience solutions.

CXApp’s Financial Transformation

Fiscal year 2024 marked a pivotal transformation for CXApp Inc., with the company achieving remarkable improvements across key performance indicators. Subscription revenue surged to 87% of total revenue, up from 78% in the previous year, while Net Revenue Retention reached a critical threshold of 101%, demonstrating strong customer satisfaction and product value1. Operational efficiency also improved significantly, with gross margins rising to 82% and a 20% reduction in operating expenses, coupled with 30% EBITDA growth2. These metrics underscore the company’s successful pivot to a software-as-a-service (SaaS) model, positioning it for sustained growth in the competitive workplace technology marketplace.

Innovative AI-Centric Solutions

The cornerstone of CXApp’s transformation has been the successful deployment of its comprehensive CXAI Platform, featuring innovative solutions such as CXAI Kiosk and CXAI VU (Skyview). These products specifically address the evolving challenges of hybrid work environments, focusing on Return to Office initiatives and employee engagement1. A significant technological milestone was achieved through the implementation of a unified code-base solution (CXAI 1.0), followed by the successful deployment of the more sophisticated CXAI 2.0 platform at a major financial services customer. This evolution represents the culmination of extensive research and development efforts to create a comprehensive ecosystem rather than fragmented point solutions.

Strategic Partnerships with Google Cloud

In a strategic move to enhance its AI capabilities, CXApp established a multi-year partnership with Google Cloud in 20241. This collaboration provides CXApp with privileged access to advanced artificial intelligence models and development tools, enabling accelerated innovation while minimizing research and development overhead costs. Additionally, the company expanded its cloud ecosystem by making its flagship products available on AWS Marketplace, enhancing accessibility for enterprise customers seeking AI-driven workplace solutions2. This multi-cloud strategy demonstrates CXApp’s commitment to platform flexibility and customer choice, positioning the company to capitalize on emerging trends in enterprise AI adoption.

by John F. Heerdink, Jr. April 3, 2025

Amazon’s Amazing Theatrical Expansion – $AMZN $SPY

Amazon has unveiled ambitious plans to significantly increase its theatrical movie releases starting in 2025, aiming to produce 12 to 15 films annually for theaters, as reported by Reuters. The announcement, made at CinemaCon in Las Vegas, featured high-profile actors promoting upcoming projects and highlighted Amazon’s strategy to leverage its MGM Studios acquisition. Yes indeed, in a bold move to reshape the film industry landscape, the e-commerce giant is set to dramatically increase its theatrical output starting in 2025. This strategic shift reflects a growing trend among streaming platforms to invest in traditional cinema experiences. The move aims to leverage the cultural impact and buzz-generating potential of theatrical releases, while also bolstering the company’s position in the competitive entertainment market.

Upcoming Amazon Film Projects

A star-studded lineup of upcoming Amazon film projects was unveiled at CinemaCon, showcasing the company’s commitment to diverse storytelling. Ryan Gosling introduced “The Fall Guy,” an action-comedy based on the 1980s TV series, while Halle Berry promoted “Never Let Go,” a thriller about a mother’s search for her missing son. Other notable announcements included:

A remake of the 1989 Patrick Swayze film “Road House,” starring Jake Gyllenhaal
“Ricky Stanicky,” a comedy featuring Zac Efron and John Cena
An untitled documentary about pop star Camila Cabello
“This Is Me…Now,” a musical film starring Jennifer Lopez

These projects seems to demonstrate Amazon’s strategy to attract top talent and create a wide range of content appealing to both theatrical audiences and streaming subscribers.

MGM Acquisition and Impact

The $8.5 billion acquisition of MGM Studios in 2022 has played a pivotal role in Amazon’s ambitious film strategy. This strategic move combines Amazon’s vast resources with MGM’s established filmmaking expertise, potentially reshaping the landscape of movie production and distribution. By leveraging MGM’s rich catalog and industry connections, Amazon aims to enhance its position in the competitive entertainment market and create a more robust pipeline for theatrical releases. The integration of MGM’s capabilities is expected to accelerate Amazon’s ability to produce high-quality, commercially viable films that can succeed both in theaters and on its Prime Video streaming platform.

Streaming and Theatrical Synergy

While ramping up theatrical releases, Amazon continues to invest heavily in its Prime Video streaming service, viewing its film strategy as complementary to its streaming offerings. This approach aims to create a synergy between theatrical and streaming content, with movies eventually making their way to Prime Video after their cinema run. Jennifer Salke, Amazon Studios chief, emphasized the company’s commitment to diverse storytelling and supporting filmmakers’ visions, aiming to attract top talent and create content appealing to both theatrical audiences and streaming subscribers. This strategy reflects a broader industry trend, with companies like Netflix and Apple also increasing investments in theatrical releases, recognizing the importance of traditional cinema experiences in building cultural impact for films.

by John F. Heerdink, Jr. April 1, 2025

Mortgage and Refinance Rates Have Shown Mixed Movements

Mortgage and refinance rates on April 1, 2025, have shown mixed movement, with some rates decreasing while others have risen slightly, presenting both opportunities and challenges for homeowners and buyers in the current housing market. The 30-year fixed-rate mortgage stands at 6.811%, down 0.055% from the previous week, while the 15-year fixed-rate mortgage is at 6.14%, also showing a decrease. For refinancing, the 30-year fixed-rate has increased to 6.84%, up 58 basis points over the past week, whereas the 15-year fixed-rate refinance loan has slightly decreased to 6.246%. These fluctuations reflect the ongoing economic uncertainty and present both opportunities and challenges for homeowners and potential buyers in the current housing market.

Economic Factors Shaping Rates

Several key economic factors are influencing mortgage rates in 2025. The Federal Reserve’s cautious approach to rate cuts has kept borrowing costs relatively high, with expectations of two quarter-point reductions later this year. Inflation trends, while moderating compared to previous years, remain a crucial driver of interest rate decisions. Any unexpected inflationary pressures could prevent significant rate declines. Additionally, the spring housing market is seeing increased activity due to higher inventory and pent-up demand, with Lawrence Yun of the National Association of Realtors noting that more choices are encouraging buyers to enter the market despite relatively stable mortgage rates.

Experts’ Predictions for 2025

Forecasts suggest mortgage rates will remain elevated throughout 2025, with experts predicting an average of around 6.3% for fixed-rate loans by year-end. Adjustable-rate mortgages may gain popularity among borrowers seeking lower initial payments amidst high borrowing costs. Fannie Mae anticipates rates moving lower within the next quarter, while some analysts expect further declines in 2026. However, the housing market’s trajectory remains uncertain, with factors such as Federal Reserve policies and inflation trends potentially influencing rate movements.

by John F. Heerdink, Jr. April 1, 2025

Discover IN8bio’s Potentially Breakthrough Next Generation γδ T cell-based T cell engager (TCE) Platform At AACR 2025 – $INAB $IBB $XBI $SNY

IN8bio, Inc. (Nasdaq: INAB), a trailblazer in gamma-delta T cell-based therapies, is turning heads at the forefront of cancer immunotherapy with its latest preclinical findings. Just this week, the company unveiled a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform that will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. This platform, which leverages the unique tumor-targeting capabilities of gamma-delta T cells, represents a significant step forward in precision oncology.

William Ho, CEO, and co-founder of IN8bio stated “T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the limitations of current CD-3 based engager therapies. Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the capacity for significant cell expansion and the specificity of bispecific engagers to drive a potent, targeted immune response against multiple target antigens. These early findings in AML and B-ALL support our broader strategy to harness the unique biology of these cells across a range of cancers.”

Revolutionizing T cell engagers (TCE’s) with Gamma-Delta T Cells

The TCE platform, highlighted through the INB-619 program, demonstrated the ability to selectively target CD19 and destroy B cells without significant secretion of cytokines such as IL-6 that can be strongly associated with adverse events such as cytokine release syndrome or CRS—a feat that underscores its potential to address critical limitations in current CD-3 targeting TCEs. Unlike conventional CAR-T approaches that often cause off-target effects, IN8bio’s technology uses a non-signaling CAR design combined with the natural selectivity of gamma-delta T cells to enhance safety and efficacy. Building on this foundation, IN8bio has also advanced its INB-600 platform, a gamma-delta T cell engager targeting CD19. This platform is designed for broader applications in oncology and autoimmune diseases, nascent market opportunity with significant interest from big pharma. Early preclinical results suggest that these therapies could deliver durable responses with improved safety profiles compared to existing CD3-based engagers.

Market Context and Growth Potential

The global CAR-T cell therapy market is experiencing rapid growth, projected to expand at a compound annual growth rate (CAGR) of 30.5% from 2025 to 2034. This surge is driven by advancements in gene-editing technologies and increasing demand for innovative cancer treatments. Within this competitive landscape, gamma-delta T cell therapies are emerging as a promising modality due to their unique biological properties, including tissue residency and low inflammatory cytokine secretion. Moreover, the broader T-cell therapy market is expected to grow from $51 billion in 2024 to $6.5 billion in 2025 and reach $20.9 billion by 2035. This growth reflects escalating investments in research and development, regulatory approvals, and rising global demand for personalized medicine.

Analyst Sentiment and Financial Position

IN8bio’s strategic advancements have not gone unnoticed by analysts. The company enjoys a “Strong Buy” consensus rating from seven analysts, with 86% recommending it as a top investment pick. Financially, IN8bio reported a net loss of $30.7 million for 2024, but maintains a solid cash position projected to fund operations through March 2026. Recent cost-saving measures and resource optimization efforts further bolster its financial stability.

Don’t Overlook The DeltEx™ Platform…

According to IN8bio’s website, The DeltEx™ platform has enabled a deep pipeline of preclinical and clinical product candidates designed to effectively target and potentially eradicate cancer cells to improve patient outcomes.

Key elements of their approach to treating cancer include:

Advanced expertise in the manufacturing of ex-vivo, expanded, activated gamma-delta T cells
First-in-class proprietary gamma-delta T cell engineering for chemotherapy resistance
Advanced next-generation, closed-system, scalable, gamma-delta T cell manufacturing
Broad applicability of our engineered DeltEx cells across multiple solid and hematological cancer indications

The innate and adaptive immune responses play critical roles in the fight against cancer. While both systems possess important functions, the most effective tumor killing occurs when they work together. Gamma-delta T cells are a unique subset of immune cells that sit at the nexus of the innate and adaptive systems and possess properties of both. Their multifunctional nature and complex receptor repertoire allow them to distinguish between healthy and cancerous cells. They can effectively kill tumor cells directly as well as recruit and activate additional immune effector cells to target and eradicate the tumor. Notably, gamma-delta T cells can eliminate cancer cells without prior antigen priming and have the ability to antigen present and trigger a broader immune cell response. These properties make gamma-delta T cells promising candidates for use in for both solid and hematological cancer therapies.

IN8bio’s DeltEx™ platform is designed to overcome many of the challenges associated with the expansion, genetic engineering and scalable manufacturing of gamma-delta T cells, allowing the team to harness their unique properties for cancer therapies. IN8bio’s core technology is a novel concept in cellular therapy, drug resistant immunotherapy, or DeltEx™ DRI, which uses intracellular engineering to generate gamma-delta T cells that are resistant to different classes of chemotherapy. These cells can be used in early and frontline treatment settings where they can survive combinations with therapeutic doses of chemotherapy. Chemotherapy, a mainstay of solid tumor treatment, can deplete and damage immune cells, including gamma-delta T cells, limiting their ability to seek and kill tumors. Chemotherapy treatment can also result in the selection of residual tumor cells that are chemotherapy resistant, which leads to disease recurrence. They have leveraged their proprietary genetic modifications to protect their DeltEx™ DRI cells from chemotherapy-induced damage, allowing for their concomitant delivery with chemotherapy so they can identify and kill residual tumor cells when the tumor is experiencing maximum chemotherapy-induced stress. This DeltEx™ DRI approach is the basis for several of our programs, including INB-200 and INB-400.

Looking Ahead At IN8bio…

As IN8bio continues to push the boundaries of cancer immunotherapy, its focus remains on delivering transformative therapies for hard-to-treat cancers like glioblastoma and acute myeloid leukemia (AML). With ongoing clinical trials demonstrating durable remissions—100% of AML patients treated with the INB-100 program remain relapse-free—the company seems to be well-positioned to make a meaningful impact on patient outcomes while seeking to drive shareholder value. Look for additional clinical updates this summer. In summary, IN8bio’s innovative platforms not only highlight its scientific ingenuity but also place it at the vanguard of a rapidly evolving market poised for exponential growth. Investors and stakeholders alike will be watching closely as the company continues to advance its pipeline and redefine possibilities in cancer treatment.

Further Afield, But Close To Home!

Sanofi To Acquire DR-0201, a targeted bispecific myeloid cell engager (MCE)…

Sanofi (SNY) and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent early clinical study data in autoimmune diseases suggest that deep B-cell depletion might have the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain. Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totaling $1.3 billion upon achievement of certain development and launch milestones. Learn more here.

About Dren Bio
Dren Bio is a privately held, clinical-stage biopharmaceutical company pioneering the discovery and development of novel first-in-class antibody therapeutics for the treatment of cancer, autoimmune, and other serious diseases. Dren Bio’s lead product candidate, DR-01, is currently being evaluated in oncology and autoimmune indications. In addition, Dren Bio’s targeted myeloid engager and phagocytosis platform is a bispecific antibody-based technology that induces potent depletion of disease-causing agents by engaging a novel phagocytic receptor that is selectively expressed on myeloid cells and activated only in the presence of the target antigen. For more information about Dren Bio and its current development pipeline, please visit Dren Bio’s website at www.drenbio.com.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Citations:
[1] https://www.globenewswire.com/news-release/2024/04/09/2860387/0/en/IN8bio-Announces-New-Preclinical-Data-for-Gamma-Delta-nsCAR-T-Cell-Therapy-Platform-at-AACR-2024.html
[2] https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-fourth-quarter-and-full-year-2024-financial
[3] https://www.rootsanalysis.com/reports/t-cell-therapies-market/261.html
[4] https://www.globenewswire.com/news-release/2025/03/13/3042590/0/en/IN8bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html
[5] https://www.stocktitan.net/news/INAB/in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-t-cell-yokboglki3gw.html
[6] https://public.com/stocks/inab/forecast-price-target
[7] https://www.gminsights.com/industry-analysis/car-t-cell-therapy-market
[8] https://www.stocktitan.net/news/INAB/
[9] https://www.biospace.com/press-releases/in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-%CE%B3%CE%B4-t-cell-engager-platform-for-cancer-immunotherapy-at-aacr-annual-meeting-2025
[10] https://www.benzinga.com/quote/INAB/analyst-ratings
[11] https://www.globenewswire.com/news-release/2025/03/25/3048565/0/en/T-Cell-Therapy-Market-Research-2025-Over-10-Approved-Therapies-and-More-than-1-200-Preclinical-Clinical-Therapy-Candidates-Global-Industry-Trends-and-Forecasts-to-2035.html
[12] https://investors.in8bio.com/news-events/press-releases
[13] https://www.globenewswire.com/news-release/2025/03/31/3052244/0/en/IN8bio-to-Present-New-Preclinical-Data-on-Novel-Gamma-Delta-%CE%B3%CE%B4-T-cell-Engager-Platform-for-Cancer-Immunotherapy-at-AACR-Annual-Meeting-2025.html
[14] https://www.nasdaq.com/market-activity/stocks/inab/analyst-research
[15] https://finance.yahoo.com/news/t-cell-therapy-market-research-104600820.html
[16] https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-updated-positive-results-phase-1-trial-inb-100
[17] https://in8bio.com
[18] https://www.wsj.com/market-data/quotes/INAB/research-ratings
[19] https://crisprmedicinenews.com/press-release-service/card/car-t-cell-therapy-market-research-2024-2025-size-forecasts-trials-and-trends-approved-car-t-t/
[20] https://www.biospace.com/press-releases/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml

by John F. Heerdink, Jr. March 31, 2025

Corcept Therapeutics Shines Amid Biotech Sector Decline: Stock Surges Over 100% Following Positive Phase 3 Trial Results – $CORT $IBB

While the broader biotech sector faced a challenging day, with the S&P 500 Biotech Index down nearly 5%, Corcept Therapeutics (CORT) emerged as a standout performer. The company’s stock skyrocketed by 109.08%, closing at $114.22—a remarkable leap from its previous close of $54.63—on the back of promising results from its pivotal Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer patients7.

Breakthrough in Platinum-Resistant Ovarian Cancer Treatment

Platinum-resistant ovarian cancer presents a dire prognosis, with limited options for effective treatment. Corcept’s experimental drug, relacorilant, in combination with nab-paclitaxel, demonstrated significant efficacy in the ROSELLA trial:

Progression-free survival improved by 30%.
Median overall survival extended by 4.5 months compared to chemotherapy alone.
A favorable safety profile with no new safety concerns.

This breakthrough offers hope to patients who have exhausted conventional therapies, addressing a critical unmet need in oncology. Dr. Alexander B. Olawaiye, an expert in gynecological oncology, emphasized the importance of these findings, stating they represent a meaningful advancement for patients battling advanced ovarian cancer.

Stock Performance: A Stunning Surge

Corcept’s stock movement on March 31 was nothing short of extraordinary:

Opening price: $94.72
Day high: $117.33 (a new 52-week high)
Closing price: $114.22
Percentage increase: 109.08%
Volume: Over 14 million shares traded, far exceeding the average daily volume of approximately 1 million shares7.

This surge reflects investor optimism fueled by the trial results and anticipation of Corcept’s upcoming New Drug Application (NDA) submission for relacorilant later this year.

A Contrast to Biotech Sector Struggles

The broader biotech market painted a starkly different picture on Monday, with many companies experiencing sharp declines amid regulatory uncertainty and macroeconomic pressures and post the resignation of a top FDA official, Peter Marks, who stated that he will not accept RRK, Jr.s ‘misinformation and lies.’ The S&P 500 Biotech Index (XBI) dropped nearly 5% (off 9.95% YTD & -14.53% over 1-Yr), and notable names like Moderna saw double-digit losses. In this challenging environment, Corcept’s success underscores how clinical breakthroughs can defy broader market trends and drive individual stock performance.

Implications for Patients and Investors

For patients, relacorilant represents a potential lifeline in the fight against platinum-resistant ovarian cancer, offering improved survival outcomes and better quality of life. For investors, Corcept’s success highlights the resilience of innovation in biotech—a reminder that groundbreaking science can prevail even amid sector-wide headwinds.

As the company prepares its NDA submission and continues its MOMENTUM trial for hypercortisolism in resistant hypertension patients, Corcept is positioned to further solidify its reputation as a leader in both oncology and endocrinology.

The Challenges of Treating Osteoarthritis

Eupraxia Pharmaceuticals: A New Approach to OA Treatment

How EP-104IAR Works

Clinical Success: Phase 2 Trials

Fast Track Designation and Future Development

Transforming Osteoarthritis Care

What Wall Street Is Saying…

Citations:

More on Advanced High-Capacity Manufacturing of MVA-based Vaccines

Continues to Strengthen its Pandemic Preparedness and Biodefense Vaccine Portfolio

More About GeoVax

A Growing Arsenal of Intellectual Property

Advancing Clinical Programs

Expanding Horizons in Oncology

A Vision for Global Health

Looking Ahead

A Recipe for Uncertainty

Economic Indicators Flashing Red

The Human Cost

Market Volatility Adds Fuel to Fire

A Path Forward?

Key Financial Highlights

Janover’s AI Edge

NVIDIA’s AI Revolution: A Parallel Tale of Innovation

NVIDIA’s Latest Developments

Drawing Parallels: The Intersection of AI Innovation

Looking Ahead

CXApp’s Financial Transformation

Innovative AI-Centric Solutions

Strategic Partnerships with Google Cloud

Upcoming Amazon Film Projects

MGM Acquisition and Impact

Streaming and Theatrical Synergy

Economic Factors Shaping Rates

Experts’ Predictions for 2025

Revolutionizing T cell engagers (TCE’s) with Gamma-Delta T Cells

Market Context and Growth Potential

Analyst Sentiment and Financial Position

Don’t Overlook The DeltEx™ Platform…

Looking Ahead At IN8bio…

Further Afield, But Close To Home!

Sanofi To Acquire DR-0201, a targeted bispecific myeloid cell engager (MCE)…

Breakthrough in Platinum-Resistant Ovarian Cancer Treatment

Stock Performance: A Stunning Surge

A Contrast to Biotech Sector Struggles

Implications for Patients and Investors

Citations:

Your Guide To Staying Informed In The Markets